2021 ICD-10-CM Code C34.81
Malignant neoplasm of overlapping sites of right bronchus and lung
Valid for Submission
| ICD-10: | C34.81 |
| Short Description: | Malignant neoplasm of ovrlp sites of right bronchus and lung |
| Long Description: | Malignant neoplasm of overlapping sites of right bronchus and lung |
Code Classification
C34.81 is a billable diagnosis code used to specify a medical diagnosis of malignant neoplasm of overlapping sites of right bronchus and lung. The code C34.81 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.
The code C34.81 is linked to some Quality Measures as part of Medicare's Quality Payment Program (QPP). When this code is used as part of a patient's medical record the following Quality Measures might apply: Lung Cancer Reporting (biopsy/cytology Specimens) , Lung Cancer Reporting (resection Specimens).
Diagnostic Related Groups - MS-DRG Mapping
The ICD-10 code C34.81 is grouped in the following groups for version MS-DRG V38.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC). applicable from 10/01/2020 through 09/30/2021.
| MS-DRG | MS-DRG Title | MCD | Relative Weight |
|---|---|---|---|
| 180 | RESPIRATORY NEOPLASMS WITH MCC | 04 | 1.7378 |
| 181 | RESPIRATORY NEOPLASMS WITH CC | 04 | 1.1209 |
| 182 | RESPIRATORY NEOPLASMS WITHOUT CC/MCC | 04 | 0.7875 |
The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.
Convert C34.81 to ICD-9 Code
The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C34.81 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.
- 162.8 - Mal neo bronch/lung NEC (Approximate Flag)
Quality Payment Program Measures
When code C34.81 is part of the patient's diagnoses the following Quality Measures apply and affect reimbursement. The objective of Medicare's Quality Measures is to improve patient care by making it more: effective, safe, efficient, patient-centered and equitable.
| Quality Measure | Description | Quality Domain | Measure Type | High Priority | Submission Methods |
|---|---|---|---|---|---|
| Lung Cancer Reporting (Biopsy/Cytology Specimens) | Pathology reports based on biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type or classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS) with an explanation included in the pathology report. | Communication and Care Coordination | Process | YES | Claims, Registry |
| Lung Cancer Reporting (Resection Specimens) | Pathology reports based on resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type. | Communication and Care Coordination | Process | YES | Claims, Registry |
Information for Patients
Lung Cancer
Also called: Bronchogenic carcinoma
Lung cancer is one of the most common cancers in the world. It is a leading cause of cancer death in men and women in the United States. Cigarette smoking causes most lung cancers. The more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. High levels of pollution, radiation and asbestos exposure may also increase risk.
Common symptoms of lung cancer include
- A cough that doesn't go away and gets worse over time
- Constant chest pain
- Coughing up blood
- Shortness of breath, wheezing, or hoarseness
- Repeated problems with pneumonia or bronchitis
- Swelling of the neck and face
- Loss of appetite or weight loss
- Fatigue
Doctors diagnose lung cancer using a physical exam, imaging, and lab tests. Treatment depends on the type, stage, and how advanced it is. Treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells.
NIH: National Cancer Institute
- After chemotherapy - discharge (Medical Encyclopedia)
- Coughing up blood (Medical Encyclopedia)
- Lung cancer (Medical Encyclopedia)
- Lung cancer - non-small cell (Medical Encyclopedia)
- Lung cancer - small cell (Medical Encyclopedia)
- Lung PET scan (Medical Encyclopedia)
- Lung surgery (Medical Encyclopedia)
- Metastatic cancer to the lung (Medical Encyclopedia)
- Solitary pulmonary nodule (Medical Encyclopedia)
[Learn More in MedlinePlus]
Code History
- FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
- FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
- FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
- FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
- FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
- FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)